

Acta endocrinologica

Chief Editor

CHRISTIAN HAMBURGER
Copenhagen

Managing Editor

K. PEDERSEN-BJERGAARD
Copenhagen

Associate Editor

JØRGEN STARUP
Copenhagen

Local Editors

J.-F. Dymling, Sweden – Chr. Hamburger, Denmark

B.-A. Lamberg, Finland – R. Nissen-Meyer, Norway

G. P. van Rees, The Netherlands

J. Tamm, Federal Republic of Germany

A. Walser, Switzerland

Consulting Editor

Rudi Borth, Toronto, Canada

Volume 67
May-August 1971

PERIODICA . COPENHAGEN

CONTENTS

<i>Authors' Index, Vol. 67</i>	VII
<i>Subject Index, Vol. 67</i>	IX
<i>Advisory Panel August 1971</i>	XXV

NUMBER 1 · MAY

<i>Pliška V., Barth T. and Thorn N. A.</i> : Some metabolites of specifically tritium labelled lysine-vasopressin. Identification by thin-layer chromatography and determination by the liquid scintillation technique	1
<i>Pliška V., Thorn N. A. and Vilhardt H.</i> : <i>In vitro</i> uptake and breakdown of tritiated lysine-vasopressin by bovine neurohypophyseal and cortical tissue	12
<i>Ortved Andersen O., Brunfeldt K. and Hansen B. A.</i> : Antibody response in the guinea pig against iodinated pig insulin preparations	23
<i>Schelin U. and Lundin P. M.</i> : An electron microscopic study of normal and neoplastic acidophil cells of the rat pituitary	29
<i>Petrusz P., Diczfalusy E. and Finney D. J.</i> : Bioimmunoassay of gonadotrophins. 1. Theoretical considerations	40
<i>Petrusz P., Diczfalusy E. and Finney D. J.</i> : Bioimmunoassay of gonadotrophins. 2. Practical aspects and tests of additivity	47
<i>Berle P. and Apostolakis M.</i> : Prolaktin-Konzentrationen im menschlichen Plasma während Schwangerschaft und Wochenbett	63
<i>Zaninovich A. A., Degrossi O. and Gotta H.</i> : Effects of oestrogens on serum thyroxine-binding globulin capacity and on the peripheral metabolism of thyroxine in patients with hepatic cirrhosis	73
<i>Lowy C., Wright A. D., Fraser T. R., Rubenstein A. H. and Spitz I.</i> : Urine excretion of insulin and growth hormone in subjects with renal failure	85
<i>Hedeland H., Dymling J.-F. and Hökfelt B.</i> : Pharmacological inhibition of adrenaline secretion following insulin induced hypoglycaemia in man. The effect of Catapresan	97
<i>Dankjær Nielsen M., Jørgensen M. and Giese J.</i> : ¹²⁵ I-labelling of angiotensin I and II	104
<i>Elema J. D., Harðonk M. J. and Arends A.</i> : Acute enzyme histochemical changes in the zona glomerulosa of the rat adrenal cortex. III. The effect of pretreatment with deoxycorticosterone acetate on the changes seen after peritoneal dialysis with 5% glucose or after total nephrectomy	117
<i>von Werder K., Smilo R. P., Hane S. and Forsham P. H.</i> : Pituitary response to stress in Cushing's disease	127
<i>Schildt B. E. and Löw H.</i> : Relationship between trauma, plasma corticosterone and reticuloendothelial function in anaesthetized mice	141
<i>Tamm J. und Voigt K. D.</i> : The effect of metopirone on the urinary excretion of testosterone and epitestosterone in normal males treated with HCG or cyproterone and in hirsute females	151
<i>Peytremann A., Veyrat R. and Muller A. F.</i> : Variations in plasma renin activity and urinary aldosterone excretion in normal subjects after salt restriction and acute pituitary inhibition with 6-dehydro-16-methylene hydrocortisone	159
<i>Sundsjord J. A.</i> : Radioimmunological determination of plasma renin activity during the menstrual cycle and during acute progesterone administration	174

<i>Szamatowicz M., Drosdowsky M. and Jayle M. F.</i> : The role of testosterone and androstenedione as precursors of <i>epitestosterone</i> in guinea pigs (<i>in vivo</i> and <i>in vitro</i> studies)	187
<i>Voûte, Jr. P. A., van der Meer J. and Staugaard-Kloosterziel W.</i> : Plasma renin activity in Wilms' tumour	197
<i>Kisch E. S.</i> : Disparity between the states of pseudopregnancy induced by reserpine and by cervical stimulation in the rat	203

NUMBER 2 · JUNE

<i>Miyai K., Amino N., Azukizawa M. and Kumahara Y.</i> : <i>In vitro</i> effects of LATS and TSH on phosphodiesterase activity in human thyroid homogenates	209
<i>Kohler H., Haeblerli A., Binswanger C., von Gruenigen C. and Studer H.</i> : Experimental procedures leading to a relative accumulation of non-thyroglobulin thyroidal iodocompounds in rat thyroid glands	216
<i>Spira O., Gordon A. and Gross J.</i> : Fractionation of 3-SS iodocompounds of the rat thyroid. I. Dialyzable and non-dialyzable iodocompounds	225
<i>Spira O., Gordon A. and Gross J.</i> : Fractionation of 3-SS iodocompounds of the rat thyroid. II. The presence and behaviour of a thyroidal iodide-binding peptide (TIP)	241
<i>Petrusz P., Robyn C. and Diczfalusy E.</i> : Antigonadotrophic profile of antisera against human gonadotrophin preparations. 1. Biological characterization of the antigens used for immunization	249
<i>Petrusz P., Robyn C. and Diczfalusy E.</i> : Antigonadotrophic profile of antisera against human gonadotrophin preparations. 2. Biological characterization of the antisera	262
<i>Nieschlag E., Wördehoff B., Gilfrich H. J., Michaelis J. und Overzier C.</i> : Kohlenhydratstoffwechsel bei Hyperthyreose. Einfluss einer thyreostatischen Therapie auf orale und intravenöse Glucosetoleranz und Insulinaktivität	277
<i>Karlberg B., Almqvist S. and Werner S.</i> : Effects of synthetic pyroglutamyl-histidyl-proline-amide on serum levels of thyrotrophin, cortisol, growth hormone, insulin and PBI in normal subjects and patients with pituitary and thyroid disorders	288
<i>Moolenaar A. J. and van Seters A. P.</i> : Gaschromatographic determination of steroids in the urine of patients with Cushing's syndrome	303
<i>Jänne O.</i> : Urinary excretion of mono- and disulphates of C ₁₉ and C ₂₁ steroids with reference to the menstrual cycle	316
<i>Kaiser R. und Geiger W.</i> : Die Östrogen- und Pregnandiolausscheidung bei HCG-Pseudograviditäten und nachfolgenden normalen Frühgraviditäten	331
<i>Cupceancu B., Neumann F. und Steinbeck H.</i> : Beeinflussung der Ovarialfunktion erwachsener weiblicher Ratten durch neonatale Behandlung mit verschiedenen Steroiden mit bekannter Gestagenwirkung	337
<i>Lee A. E.</i> : The limitations of using mouse uterine weight as an assay of oestrogen antagonism	345
<i>Holmdahl T. H., Johansson E. D. B. and Wide L.</i> : The site of progesterone production in early pregnancy	353
<i>Nillius S. J. and Wide L.</i> : Effects of progesterone on the serum levels of FSH and LH in postmenopausal women treated with oestrogen	362
<i>Goldzieher J. W. and Williams M. C.</i> : Urinary testosterone glucuronide as a measure of endogenous testosterone production	371

<i>Hansson V., Tvøeter K. J. and Altramadal A.:</i> Uptake and binding of 5 α -dihydrotestosterone in rat ventral prostate <i>in vivo</i>	384
<i>Toft H., Buus O. and Nielsen E.:</i> Vasopressin in the diagnostic evaluation of pituitary and hypothalamic function	393
<i>Persson I., Gyntelberg F., Heding L. G. and Boss-Nielsen J.:</i> Pancreatic-glucagon-like immunoreactivity after intravenous insulin in normals and chronic-pancreatitis patients	401
<i>Nieschlag E., Wombacher H., Kroeger F. J. und Habighorst L. V.:</i> Therapic eines metastasierenden Inselzelltumors mit Streptozotocin	405

NUMBER 3 · JULY

<i>Robyn C., L'Hermite M., Petrusz P. and Diczfalusy E.:</i> Potency estimates of human gonadotrophins by a bioassay and three immunoassay methods	417
<i>Mathies D. L. and Diczfalusy E.:</i> Relationships between physico-chemical, immunological and biological properties of human chorionic gonadotrophin. 1. Properties of human chorionic gonadotrophin as found in tissues and body fluids ..	434
<i>Mathies D. L., Petrusz P. and Diczfalusy E.:</i> Relationships between physico-chemical, immunological and biological properties of human chorionic gonadotrophin. 2. Biological and immunological behaviour of several species of human chorionic gonadotrophin	445
<i>Warner S. M. and Frasier S. D.:</i> The early antibody response to human growth hormone	457
<i>Hipkin L. J.:</i> The effect of corticotrophin on the rat uterine weight response to human chorionic gonadotrophin	463
<i>Woodings D. F. and Young P.:</i> A rapid test of adrenocortical function using Homactid (synthetic α_h^{1-28} ACTH)	470
<i>Littmann K.-P., Gerdes H. und Winter G.:</i> Kinetik und Charakterisierung der Östradiolsensitiven 17 β -Hydroxysteroiddehydrogenasen in der menschlichen Leber	473
<i>Sundsjord J. A.:</i> Plasma renin activity and aldosterone excretion during prolonged progesterone administration	483
<i>Hobson B.:</i> Immunoassay of human pituitary luteinizing hormone (LH) in urine. A comparison between a haemagglutination and radioimmunosorbent method ..	491
<i>Kaalund Jensen H. and Blichert-Toft M.:</i> Investigation of pituitary-adrenocortical function in the elderly during standardized operations and postoperative intravenous metyrapone test assessed by plasma cortisol, plasma compound S and eosinophil cell determinations	495
<i>Boss N., Kluge F., Müller O. A., Pickardt C. R. and Scriba P. C.:</i> Quantitative assay of the suppressive effect of synthetic corticoids in man. Evaluation of the circadian rhythm of serum cortisol after single oral doses of fluocortolone and prednisolone	508
<i>Wenzel M.:</i> Oxydation des Anabolikums 1-Methyl-androst-1-en-17 β -ol-3-on mit Wasserstofftransfer auf Östron. <i>In vitro</i> Untersuchungen mit Schnitten von Rattenorganen	517
<i>Melville E., Kelly R. W. and Mitchell F. L.:</i> Failure to detect 3 β ,11 β ,17 α ,21-tetrahydroxy-5-pregnen-20-one in plasma obtained from human umbilical cords and human infant urine	531
<i>Simmons J. E.:</i> Uptake of [1,2- 3 H] testosterone in oestrogenized male rats	535
<i>Steinbeck H., Cupceancu B., Mehring M. and Neuman F.:</i> Influence of neonatal gestagen injection on the differentiation of psychosexuality in female rats	544

<i>Claassen V., Morsink L. and de Wachter A. M.</i> : Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston®) on ovulation in the rat, rabbit and monkey	551
<i>Platt D. and Frackenhohl H.</i> : Peptidyl peptide hydrolases, cathepsin and collagenase (?) of the rat uterus during postpartum involution	563
<i>Becker H., Berle P., Wallé A. and Voigt K. D.</i> : Influence of late gestation and early puerperium on lipid and carbohydrate metabolism in normal females ...	570
<i>Brandau H. und Brandau L.</i> : Enzymologische Studien am Arrhenoblastom	577
<i>Moore H. C., Borvendeg J. and Wilson K.</i> : The effect of foetal removal on the blood pressure in steroid hypertensive rats	590
<i>Berle P. und Apostolakis M.</i> : Inkubationsversuche mit einem Antihuman-Prolaktin	597
<i>Wägar G.</i> : Increase in thyroid uptake of radioiodine induced by actinomycin D	605
<i>Siersbæk-Nielsen K. and Møllholm Hansen J.</i> : The binding capacity of thyroxine-binding globulin in cerebrospinal fluid	616

NUMBER 4 · AUGUST

<i>Vingerhoeds A. C. M., der Kinderen P. J., Thijssen J. H. H. and Scharwz F.</i> : Detection of an ACTH-secreting bronchial carcinoid tumour eighteen months after adrenalectomy for Cushing's syndrome	625
<i>Simonsson B.</i> : Uptake of ³ H-cortisol by rabbit polymorphonuclear leukocytes <i>in vitro</i>	634
<i>Kakihana R., Butte J. C., Hathaway A. & Noble E. P.</i> : Adrenocortical response to ethanol in mice: Modification by chronic ethanol consumption	653
<i>Oh R. and Tamaoki B.</i> : Occurrence of 19-oxoandrost-4-ene-3,17-dione in the course of oestrogen biosynthesis by equine testicular microsomes	665
<i>Cohen S. L.</i> : The excretion of »labile« oestrogens during human pregnancy. I. Normal pregnancy	677
<i>Cohen S. L.</i> : The excretion of »labile« oestrogens during human pregnancy. II. Diabetic pregnancy	687
<i>Patwardhan V. V. and Lanthier A.</i> : The <i>in vitro</i> formation of androstenedione from C ₂₁ steroids by follicles isolated from human ovaries. A time study	698
<i>Pal S. B.</i> : The pattern of urinary excretion of individual 17-ketosteroids in rhesus monkeys	711
<i>Adhikary P. M. and Harkness R. A.</i> : The use of carbon skeleton chromatography for the detection of steroid drug metabolites: The metabolism of anabolic steroids in man	721
<i>Bird C. E., Green R. N., Calandra R. S., Connolly J. G. and Clark A. F.</i> : Kinetics of ³ H-testosterone metabolism in patients with carcinoma of the prostate: Effects of oestrogen administration	733
<i>Kowalewski K., Heron F. and Russell J. C.</i> : Effect of sex hormones on the metabolism of collagen and ⁴⁵ Ca by the bones of young gonadectomized rats	740
<i>Johnsen S. G.</i> : Evaluation of gonadotrophin analyses in male hypogonadism ..	756
<i>Quabbe H.-J., Helge H. and Kubicki S.</i> : Nocturnal growth hormone secretion: Correlation with sleeping EEG in adults and pattern in children and adolescents with non-pituitary dwarfism, overgrowth and with obesity	767
<i>Ljunggren J.-G., Sedvall G., Levin K. and Fyrö B.</i> : Influence of the lithium ion on the biosynthesis of thyroxine and thyroglobulin in the rat	784
<i>Liewendahl K., Tötterman J. and Lamberg B.-A.</i> : Determination of total and free serum thyroxine in thyroid diseases	793

II. Medizinische Klinik der Universität München, Deutschland

QUANTITATIVE ASSAY OF THE
SUPPRESSIVE EFFECT OF SYNTHETIC CORTICOIDS IN MAN

*Evaluation of the circadian rhythm of
serum cortisol after single oral doses of fluocortolone
and prednisolone*

By

*N. Boss, F. Kluge, O. A. Müller, C. R. Pickardt
and P. C. Scriba**

A B S T R A C T

The suppressive effect of synthetic corticoids on the human hypothalamic-pituitary-adrenal axis was analyzed by determining the integral differences of the circadian serum cortisol levels between control subjects (N = 25) and subjects receiving different single oral doses of prednisolone (N = 29) or fluocortolone (N = 36). Linear log dose-response curves were obtained by this procedure with the indices of precision for prednisolone of $\lambda = 0.221$ and for fluocortolone of $\lambda = 0.149$. With this method it is possible to compare the suppressive effect of different corticoids. The relative suppressive potency of corticoids should not be expressed by ratios or factors, but rather by log dose-response curves of the type: $\text{response} = b \cdot \log \text{dose} + a$.

This study was conducted in order to develop a procedure for quantitating the suppressive effect of single oral doses of synthetic corticoids on the hypothalamic-pituitary-adrenal axis in man, since the available data in the literature were considered to be unsatisfactory (*Hedner 1967; Radvila et al. 1969; Hochheuser et al. 1969; Bethge 1970*). *Hedner (1967)* administered orally four synthetic corticoids at four equipotential dose levels at midnight and considered the reduction in the 8.00 a. m. plasma corticosteroid values as the

Herrn Prof. Dr. med. H. Schwiegl zum 65. Geburtstag gewidmet.

* Supported by the Deutsche Forschungsgemeinschaft (SFB 51).

suppressive effect. Rectilinear log dose-response curves were obtained with indices of precision from $\lambda = 0.19$ to $\lambda = 0.39$. *Radvila et al.* (1969) followed the circadian variation of serum 11-hydroxycorticosteroids after oral corticoid administration, but only single dose levels of dexamethasone and triamcinolone were used.

The present study was performed in order to obtain linear log dose-response curves for prednisolone and fluocortolone with reasonable indices of precision (λ). Therefore various dose levels of these corticoids were administered orally and the curves of the circadian serum cortisol values were subsequently analyzed until the intersection with the normal circadian cortisol profile. By this means, both the degree and duration of the suppression of the hypothalamic-pituitary-adrenal axis by a single corticoid dose could be taken as response.

Preliminary results of this study have been reported (*Boss et al.* 1970; *Scriba et al.* 1970a).

MATERIAL AND METHODS

The subjects under study were hospitalized for various non-acute, non-endocrine diseases. Subjects were either selected for the control group or suppressed with only one single dose of the synthetic corticoids used, usually during convalescence shortly before being discharged from the hospital. The control group (N = 25 males) had an average weight of 73.0 ± 10.6 kg and were 41.7 ± 16.1 years of age (mean \pm sd). The prednisolone group (N = 29 males) and the fluocortolone group (N = 36 males) had average weights of respectively 75.2 ± 11.1 kg, and 70.1 ± 11.7 kg, and were respectively 41.0 ± 14.0 and 41.5 ± 15.5 years of age. The two totally adrenalectomized patients were both females (M. M., 43 years; H. M., 46 years). Adrenalectomy in these cases was performed several years before this study because of Cushing's syndrome with bilateral adrenal hyperplasia.

Prednisolone (Pregna-1,4-dien-11 β ,17 α ,21-triol-3,20-dione) and fluocortolone (6 α -fluoro-16 α -methyl-pregna-1,4-dien-11 β ,21-diol-3,20-dione) were given orally as tablets (5 mg) at 7.00 a. m. in doses indicated in Figs. 3 and 4. Blood was collected in polystyrol tubes at the intervals indicated in Figs. 1, 5 and 6; the serum was stored at -20°C until determination.

Serum cortisol was determined fluorimetrically as previously described (*Kluge et al.* 1970; *Scriba et al.* 1970b). The suppressive effect of prednisolone and fluocortolone on the circadian rhythm of serum cortisol was determined as shown in Figs. 1 and 2.

Statistical analysis was performed as indicated throughout the text (*Wallis & Roberts* 1969; *Gaddum* 1953). The authors are indebted to Dr. P. Kuhbier, München, for his valuable help in the statistical evaluation.

RESULTS

The suppressive effect of various single oral doses of synthetic corticoids administered at 7.00 a. m. was determined by calculating the integral differences





Fig. 1 a and b.

Example of the suppression of circadian serum cortisol levels by a single oral dose of corticoid, i. e. fluocortolone at 7.00 a. m. The circadian rhythm of serum cortisol levels of the controls (mean \pm sd, N = 25) for 48 h is represented by the upper curve in both parts of Fig. 1 (+).

a) *Measured curve.*

The serum cortisol levels measured in a subject given 10 mg fluocortolone at 7.00 a. m. are shown as an example by the lower curve (o). Since the values of the corticoid subject at 6.00 a. m. on the first and third day are different from the mean values of the controls, each cortisol value of the corticoid treated subjects, receiving fluocortolone or prednisolone, had to be corrected.

b) *Corrected curve.*

The corrections for the initial 6.00 a. m. and for subsequent values were performed by multiplying the measured cortisol values of each corticoid treated subject (here fluocortolone) by a factor F, derived from dividing the 6.00 a. m. values of the first and third day of the control group by the 6.00 a. m. values of the first and third day of each corticoid treated subject. Analogous corrections were then applied to the cortisol levels of each corticoid treated subject receiving either fluocortolone or prednisolone. The corrected levels of serum cortisol of the subject receiving 10 mg fluocortolone are shown in the lower curve (o). The hatched area between the control and the corrected corticoid curve was calculated as the difference between the integrals of the two curves (Δ integral = suppressive effect) from the start at 6.00 a. m. until the intersection (SP).




Fig. 2.

Schematic presentation of the calculation of the suppressive effect of a single oral dose of corticoid, i. e. fluocortolone or prednisolone.

SP

The difference of the integrals ($\Delta \int_0^{SP}$) of the circadian cortisol curves of the controls (y_N) and of a corticoid subject (y) from the start ($t = 0$) until the intersection (SP) was calculated as the sum of the single areas F_1 to F_n :

$$\Delta \int_0^{SP} = F_1 + F_2 + \dots + F_{n-1} + F_n$$

$$F_1 = \left[(y_{N_0} - y_0) + (y_{N_1} - y_1) \right] \cdot \frac{t}{2}$$

$$F_2 = \begin{matrix} \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \end{matrix}$$

$$F_{n-1} = \left[(y_{N_{n-2}} - y_{n-2}) + (y_{N_{n-1}} - y_{n-1}) \right] \cdot \frac{t}{2}$$

$$F_n = (y_{N_{n-1}} - y_{n-1}) \cdot \frac{h}{2}$$

h was derived from geometric formulae. The calculation was performed with a computer (Olivetti Programma 102). The authors are indebted to Dr. Peter v. Breitenlohner, München, for setting up the programme for the computer.

between the circadian cortisol levels in the controls and in the subjects receiving corticoids. There was a linear log dose-response relationship between the log dose of prednisolone, or of flucortolone, and the suppressive effect $\Delta \int_{0}^{SP}$. This was shown for the absolute dose of corticoid in mg (Fig. 3) and also for μg per kg body weight (Fig. 4). The correlation coefficients (r) and the indices of precision (λ) for both prednisolone and flucortolone are satisfactory (Figs. 3 and 4), in view of the fact, that the model used might be considered as a method of bioassay in the human subject.




Fig. 3.

SP
 Suppressive effect ($\Delta \int_{0}^{SP}$) of prednisolone (●) and of flucortolone (○) plotted as
 log dose in mg.

Single values and means \pm SD of the suppressive effect, calculated as described in Fig. 2, are shown for the log dose of corticoids, given as a single dose at 7.00 a.m. Linear log dose-response curves were calculated from $y = bx + a$ with

$$\text{the regression: } b = \frac{\sum xy - N\bar{x}\bar{y}}{\sum x^2 - N\bar{x}^2},$$

the suppression of the fictive dose of 1 mg:

$$a = y \text{ for } x = 0,$$

$$\text{the correlation: } r = \frac{\sum xy - N\bar{x}\bar{y}}{\sqrt{(\sum x^2 - N\bar{x}^2)(\sum y^2 - N\bar{y}^2)}},$$

$$\text{and the index of precision: } \lambda = \frac{s_b}{b}; \text{ where } s_b = \frac{s_y}{s_x} \sqrt{\frac{1-r^2}{n-2}}.$$

The two dose-response curves intersect at IP.




Fig. 4.

SP
 Suppressive effect (Δ) of prednisolone (●) and of fluocortolone (○) plotted as
 $\frac{\Delta}{\circ}$
 log dose in μg per kg body weight.

The linear log dose-response curves were calculated as described in Fig. 3.

Apparently the relative suppressive potencies of the two corticoids compared cannot be characterized by a simple factor or ratio (*Hedner 1967*). Instead, the suppressive effect has to be expressed by dose-response curves $\frac{\Delta}{\circ} = b \cdot \log$ dose + a (Figs. 3 and 4). The two curves obtained for prednisolone and for fluocortolone are slightly different with regard to their regressions (b). The difference between the regressions is hardly of statistical significance when the dose is plotted (Fig. 3) in mg ($P < 0.15$), or (Fig. 4) in μg per kg body weight ($P < 0.2$).

However, the assumption that the two curves intersect at IP (Figs. 3 and 4) is supported by the fact, that the values for a, which denote the suppression at doses of respectively 1 mg, and 1 μg per kg body weight, are significantly different ($P < 0.05$; prednisolone: N = 29, fluocortolone: N = 36). The log dose-response curves do not cross at the intersection of the ordinate and abscissa, since the log of a dose of zero would be indefinite.

No significant difference was found for the various corresponding groups receiving prednisolone or fluocortolone in doses ranging from 2.5 to 50 mg (Figs. 3 and 4). On the other hand, a dose as low as 2.5 mg of prednisolone or

of fluocortolone suppressed the cortisol levels significantly as compared with the controls ($P < 0.0125$).

The slight difference in the regressions (b) of the two dose-response curves for prednisolone and fluocortolone may be derived from Fig. 5. The suppressive effect of prednisolone in lower doses, e. g. 20 mg, is more rapid in onset and also more marked than the effect of fluocortolone, whereas the effect of fluocortolone appears to last somewhat longer. These differences in onset of the suppressive effect diminish with higher doses. However, the longer duration of the fluocortolone effect may possibly cause a more pronounced suppressive effect of fluocortolone at doses above approximately 100 mg (Figs. 3 and 4).

Neither prednisolone nor fluocortolone show any fluorescence in the alcohol-sulphuric acid reagent. However, an important question to be answered is, whether the metabolites of these synthetic corticoids interfere with the fluorimetric determination. The fluorescence of serum from adrenalectomized patients (Fig. 6) was therefore determined for 48 h after the administration of 50 mg prednisolone, and fluocortolone respectively. No evidence of any such fluorescent metabolites was obtained.




Fig. 5.

Dynamics of the suppression induced by prednisolone and by fluocortolone. The mean values \pm sd of circadian serum cortisol levels of controls ($N = 25$) and of subjects receiving 20 mg prednisolone ($N = 9$) or 20 mg fluocortolone ($N = 5$) at 7.00 a. m. are shown.




Fig. 6.

Basic fluorescence in totally adrenalectomized patients after 50 mg prednisolone or fluocortolone at 7.00 a. m.

The circadian cortisol curve of normal controls (+) and normal subjects receiving 50 mg prednisolone (●) or fluocortolone (○) were compared with the fluorimetric values of serum from totally adrenalectomized patients (M.M., H.M.). Totally adrenalectomized patients were taken off cortisol replacement therapy 18 h before the first serum cortisol determination (6.00 a. m.) and received 50 mg of prednisolone (●) or fluocortolone (○) at 7.00 a. m. No evidence for the presence of any fluorescent metabolites of these synthetic corticoids was obtained. The values were close to the basic fluorescence of »cortisolfree« serum (1–2 $\mu\text{g}/100\text{ ml}$) in this assay (Kluge *et al.* 1970).

DISCUSSION

The proposed method for calculating the integral differences of serum cortisol levels between controls and subjects receiving synthetic corticoids, make it possible to quantitate the suppressive effect of corticoids in man. It shows that any analysis of the suppressive action of different corticoids should take into account both the degree and duration of suppression. This conclusion is thought to be valid despite the recent observation of Hellman *et al.* (1970), that cortisol is secreted episodically.

The approach presented in this paper may provide a means of comparing the suppressive potency of various corticoids. The relative potencies cannot be expressed by simple ratios or factors (Hedner 1967). Rather, dose-response curves have to be obtained as demonstrated under Results, since the relation between the potencies is not constant throughout the whole range of doses administered. It would appear to be justifiable to look for analogous dose-response relationships for other corticoid effects in man, e. g. diabetogenic, anti-inflammatory, ulcerogenic and other actions of corticoids.

It remains, however, an open question whether the suppressive effects of long

term corticoid therapy and of single oral corticoid doses, as described in this paper, are the same for all synthetic corticoids.

ACKNOWLEDGMENT

The authors are indebted to Mrs. R. Fröhlich for excellent technical assistance.

REFERENCES

- Bethge H.*: *Klin. Wschr.* 48 (1970) 317.
Boss N., Kluge F., Gerb A. C., Hofmann H. & Scriba P. C.: *Sympos. Dtsch. Ges. Endokr.* 16 (1970) 368.
Gaddum J. H.: *Pharmacol. Rev.* 5 (1953) 87.
Hedner L. P.: *J. Endocr.* 37 (1967) 57.
Hellman L., Nakada F., Curti J., Weitzman E. D., Kream J., Roffwarg S., Ellman S., Fukushima D. K. & Gallagher T. F.: *J. clin. Endocr.* 30 (1970) 411.
Hochheuser W., Gerb A., Müller-Bardorff M. & Thiele H.: *Dtsch. med. Wschr.* 94 (1969) 2488.
Kluge F., Gerb A. C., Boss N., Fahlbusch R. & Scriba P. C.: *Klin. Wschr.* 48 (1970) 929.
Radvila A., Dettwiler W., Rohner R. & Studer H.: *Schweiz. med. Wschr.* 99 (1969) 709.
Scriba P. C., Boss N., Gerb A. C., Kluge F. & Müller O. A.: 3rd Intern. Congr. Hormon. Steroids, *Excerpta med. (Amst.) Intern. Congr. ser. no. 210 (1970a)* 177.
Scriba P. C., Gerb A. C., Kluge F., Boss N. & Müller O. A.: *Z. analyt. Chem.* 252 (1970b) 284.
Wallis W. A. & Roberts H. V.: *Methoden der Statistik.* Rowohlt, Taschenbuch (1969).

Received on November 13th, 1970.